Fermenta Biotech Q1 FY26: standalone PAT Rs 14.99 cr, revenue Rs 111.84 cr

Revenue DeclineExceptional ItemResults View source PDF Explain this filing

FERMENTA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-12.8%Reaction day

₹547.40

prior close

₹460.00

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.2%-12.6% vs market

Pharmaceuticals peers, median of 164sector+0.1%-12.9% vs sector

On the reaction day the stock moved 12.6 pts less than Nifty Microcap 250 and 12.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-2.5

10m

-1.8

15m

-1.7

30m

-2.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-12.8-0.2-12.6+0.1-12.9

Next day

-13.3+0.2-13.5-0.4-12.8

-16.1+0.4-16.5+0.1-16.3

-17.8+0.4-18.2-0.4-17.4

-16.1+0.6-16.7-0.9-15.3

-16.5+0.9-17.4-0.5-16.0

-15.2+0.9-16.1-1.0-14.2

15d

-10.8+0.9-11.7-0.6-10.2

-13.2+2.3-15.6+1.1-14.4

-4.7-1.1-3.6-3.1-1.6

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 164Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Fermenta Biotech reported Q1 FY26 standalone revenue of Rs 111.84 cr, up 1.8% YoY. Standalone PAT was Rs 14.99 cr versus Rs 16.23 cr before exceptional items last year, down about 8%. On a consolidated basis, revenue fell 10.6% to Rs 121.82 cr and net profit dropped sharply to Rs 9.53 cr from Rs 21.60 cr. Auditors SRBC and Co LLP issued an unmodified review opinion. Q4 FY26 carried an exceptional gain of Rs 9.07 cr from reversal of old receivables provision.

Likely market impact

Marginal standalone growth but weak consolidated performance. PAT lower year on year. Auditor view clean. Watch for recovery in coming quarters.